Comparison of proportion of positive sentiment for efficacy among biological disease modifying anti-rheumatic drugs
| Abatacept 86.04% | Adalimumab 85.29% | Certolizumab 83.08% | Etanercept 87.06% | Golimumab 86.27% | Infliximab 84.94% | Rituximab 84.64% | Tocilizumab 87.24% | Tofacitinib 81.21% | |
| Abatacept 86.04% | NA | DUP | DUP | DUP | DUP | DUP | DUP | DUP | DUP |
| Adalimumab 85.29% | 0.75% | NA | DUP | DUP | DUP | DUP | DUP | DUP | DUP |
| Certolizumab 83.08% | 2.96% | 2.21% | NA | DUP | DUP | DUP | DUP | DUP | DUP |
| Etanercept 87.06% | 1.02% | *1.77% | *3.98% | NA | DUP | DUP | DUP | DUP | DUP |
| Golimumab 86.27% | 0.23% | 0.98% | 3.19% | 0.79% | NA | DUP | DUP | DUP | DUP |
| Infliximab 84.94% | 1.10% | 0.35% | 1.86% | *2.12% | 1.34% | NA | DUP | DUP | DUP |
| Rituximab 84.64% | 1.40% | 0.65% | 1.56% | *2.42% | 1.63% | 0.30% | NA | DUP | DUP |
| Tocilizumab 87.24% | 1.20% | 1.95% | 4.16% | 0.18% | 0.97% | 2.30% | 2.60% | NA | DUP |
| Tofacitinib 81.21% | *4.83% | *4.08% | 1.87% | *5.85% | 5.06% | 3.73% | 3.43% | *6.03% | NA |
*p<0.05.
DUP, duplicate value; NA, not applicable.